Skip to main content

Market Information

Market Information

Evidently, in considering whether or not to submit a finished pharmaceutical product (FPP) or active pharmaceutical ingredient (API) to WHO for evaluation for prequalification, manufacturers will seek to understand and review the potential donor-funded market for the product concerned.

WHO does not generate its own information regarding markets for quality-assured APIs and FPPs. Rather, its role focuses on verifying the quality of urgently-needed APIs and FPPs, and, when needed, facilitating improvements to their quality.

However, market information is prepared and made publicly by several other organizations. It includes substantial "market landscape" reports that both review recent product procurement (within a specific therapeutic area), including pricing, and outline anticipated market trends. Additionally, some organizations make publicly available information regarding what FPPs have been procured, at what price, with their funds, and/or what they are currently procuring (including price range information).

Current bidding opportunities will also provide manufacturers with important information about procurement opportunities.

As well as submitting an API or FPP for evaluation for prequalification, applicants may consider submission of FPPs for assessment by the Expert Review Panel (ERP). WHO-prequalified or products approved by a stringent regulatory authority are not available on the market for all needed medicines, or may be in short supply. Procurers may therefore find themselves in the position of having to urgently procure products about which little is known in terms of quality risk. ERP was created to help procurers assess such risk. The results of ERP assessments enable procurers — such as the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria and UNFPA (United Nations Population Fund) — to make an informed decision regarding time-limited procurement of the products assessed. ERP assessment is therefore another route to markets.

Links to all this information can be found below.

Contraceptive commodity funding during the COVID-19 pandemic, January 2023 (Reproductive Health Supplies Coalition)

Disease narrative for hepatitis C, February 2020 (Unitaid) 

Disease narrative for HIV, November 2019 (Unitaid)

Disease narrative for malaria, December 2019 (Unitaid)

Disease narrative for tuberculosis, December 2019 (Unitaid)

Family planning market report, December 2022 (Clinton Health Access Initiative & Reproductive Health Supplies Coalition)

From guidelines to reality: Accelerating access to prevention and treatment of paediatric HIV: MSF Access Campaign Technical Brief (December 2019, Médecins Sans Frontières)

Global contraceptive commodity gap analysis, 2019, (Reproductive Health Supplies Coalition)

2022 HIV market report: the state of the HIV market in low- and middle-income countries (12 October 2021, Clinton Health Access Initiative)

HIV mid-year market memo 2022 (31 May 2022, Clinton Health Access Initiative)

Paired pandemics: ensuring HIV care continuity and market stability during COVID-19 (12 November 2020, Clinton Health Access Initiative)

Untangling the web of antiretroviral price reductions: report series (Médecins Sans Frontières)

Medicines Eligible Product Lists (The Global Fund):

Pooled procurement mechanism reference pricing: advanced HIV disease products, Q2 2020 (The Global Fund)

Pooled procurement mechanism reference pricing: antimalarial medicines, Q1, 2021 (The Global Fund)

Pooled procurement mechanism reference pricing: ARVs, March 2021 (The Global Fund)

Pooled procurement mechanism reference pricing: strategic medicines used in HIV programs, April 2021 (The Global Fund)

UNFPA procurement statistics for 2020

The Medicines Patent Pool (MPP) is a United Nations-backed public health organization working to increase access to HIV, viral hepatitis C and tuberculosis treatments in low- and middle-income countries. Through its innovative business model, the MPP partners with governments, industry, civil society, international organisations, patient groups and other stakeholders to forecast, prioritize and license needed medicines. The organization encourages generic manufacture and the development of new formulations through patent pooling.

MPP's MedsPal (the Medicines Patents & Licences Database) contains comprehensive information on the patent and licensing status of selected HIV, hepatitis C and tuberculosis medicines

The MPP was founded and remains fully funded by Unitaid.